ActinineCAS# 407-64-7 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 407-64-7 | SDF | Download SDF |
PubChem ID | 725 | Appearance | Powder |
Formula | C7H15NO2 | M.Wt | 145.2 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 4-(trimethylazaniumyl)butanoate | ||
SMILES | C[N+](C)(C)CCCC(=O)[O-] | ||
Standard InChIKey | JHPNVNIEXXLNTR-UHFFFAOYSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Actinine is the biosynthetic intermed, in synth. of Carnitine BDS79-T. |
Actinine Dilution Calculator
Actinine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 6.8871 mL | 34.4353 mL | 68.8705 mL | 137.741 mL | 172.1763 mL |
5 mM | 1.3774 mL | 6.8871 mL | 13.7741 mL | 27.5482 mL | 34.4353 mL |
10 mM | 0.6887 mL | 3.4435 mL | 6.8871 mL | 13.7741 mL | 17.2176 mL |
50 mM | 0.1377 mL | 0.6887 mL | 1.3774 mL | 2.7548 mL | 3.4435 mL |
100 mM | 0.0689 mL | 0.3444 mL | 0.6887 mL | 1.3774 mL | 1.7218 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- O-Phospho-L-serine
Catalog No.:BCC6578
CAS No.:407-41-0
- Taxifolin 3-O-beta-D-xylopyranoside
Catalog No.:BCN5458
CAS No.:40672-47-7
- Cornoside
Catalog No.:BCN7575
CAS No.:40661-45-8
- IKK-2 inhibitor VIII
Catalog No.:BCC1642
CAS No.:406209-26-5
- ACHP
Catalog No.:BCC6223
CAS No.:406208-42-2
- DSP-4
Catalog No.:BCC7527
CAS No.:40616-75-9
- DMT-T
Catalog No.:BCC2843
CAS No.:40615-39-2
- DMT-Cl
Catalog No.:BCC2799
CAS No.:40615-36-9
- Cirazoline hydrochloride
Catalog No.:BCC6833
CAS No.:40600-13-3
- C34
Catalog No.:BCC5603
CAS No.:40592-88-9
- GW3965 HCl
Catalog No.:BCC3790
CAS No.:405911-17-3
- GW3965
Catalog No.:BCC1612
CAS No.:405911-09-3
- (-)-Bicuculline methiodide
Catalog No.:BCC7387
CAS No.:40709-69-1
- (+)-Nerolidol
Catalog No.:BCC8219
CAS No.:142-50-7
- CaCCinh-A01
Catalog No.:BCC6314
CAS No.:407587-33-1
- 1,7-Diepi-8,15-cedranediol
Catalog No.:BCN5460
CAS No.:40768-81-8
- FPL 55712
Catalog No.:BCC7310
CAS No.:40785-97-5
- PD 146176
Catalog No.:BCC7504
CAS No.:4079-26-9
- H-D-Asp(OBzl)-OBzl.TosOH
Catalog No.:BCC2900
CAS No.:4079-64-5
- MDL 72222
Catalog No.:BCC6733
CAS No.:40796-97-2
- Suprofen
Catalog No.:BCC4943
CAS No.:40828-46-4
- 3,5-Dihydroxy-1-(3,4-dihydroxyphenyl)-7-(4-hydroxyphenyl)heptane
Catalog No.:BCN7165
CAS No.:408324-00-5
- 3,5-Dihydroxy-1,7-bis(3,4-dihydroxyphenyl)heptane
Catalog No.:BCN7494
CAS No.:408324-01-6
- H-Tyr-OEt.HCl
Catalog No.:BCC3125
CAS No.:4089-07-0
[Expression of nephrin, podocin and a-actinine-4 in renal tissue of patients with proteinuria].[Pubmed:19936002]
Nefrologia. 2009;29(6):569-75.
INTRODUCTION: Slit diaphragm and/or podocyte's cytoskeleton alterations are related to proteinuria and nephrotic syndrome. In our population, focal and segmental glomerulosclerosis causing nephrotic syndrome is the more frequent biopsy demonstrated glomerulopathy. Our aim was search for alterations in some slit diaphragm-associated proteins in patients with nephrotic range proteinuria. METHODS: Renal tissue from 40 patients with nephrotic range proteinuria, 10 patients with non-nephrotic proteinuria, 3 with isolated hematuria, and 10 samples of normal renal tissue (deceased donors) were studied, by indirect immunofluorescence, for expression of nephrin, podocin, and alpha-actinin-4. RESULTS: Expression of these proteins was lineal, homogeneous, in the glomerular capillary walls in normal renal tissue and in patients with isolated hematuria. In nephrotic proteinuria this normal appearance was altered and immunostaining showed a fine granular appearance. In 18 cases (45%) of patients with nephrotic proteinuria and 3 cases (30%) of patients with non-nephrotic proteinuria there was loss of at least one of these proteins (p = 0.49). These alterations were found in the diverse glomerulopathies more frequently causing nephrotic syndrome. CONCLUSIONS: In nephrotic range proteinuria redistribution or loss of expression of slit diaphragm-associated proteins is very frequent. In many of our cases this fact could be more a consequence than a cause of proteinuria. These alterations can be also evidenced in patients with non-nephrotic proteinuria.